

1 MAJOR ARTICLE

2 **Community-based surveys for *Plasmodium falciparum* *pfhrp2* and *pfhrp3* gene deletions in**
3 **selected regions of mainland Tanzania**

4 Catherine Bakari^{1,2}, Sophie Jones^{3,4}, Gireesh Subramaniam^{3,5}, Celine I. Mandara^{2,6}, Mercy G.
5 Chiduo², Susan Rumisha⁷ Frank Chacky⁸, Fabrizio Molteni⁸, Renata Mandike⁸, Sigsbert Mkude⁸,
6 Ritha Njau¹⁰, Camelia Herman^{3,9}, Douglas P. Nace³, Ally Mohamed⁷, Venkatachalam
7 Udhayakumar³, Caleb K. Kibet¹, Steven G. Nyanjom¹, Eric Rogier³, Deus S. Ishengoma^{7,11,12*}

8

9 ¹Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya

10 ²National Institute for Medical Research, Tanga Research Centre, Tanga, Tanzania

11 ³Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and
12 Prevention, Atlanta, GA, USA

13 ⁴Williams Consulting, Baltimore, Maryland, USA

14 ⁵Oak Ridge Institute for Science and Education, Atlanta, Georgia, USA ⁶Kilimanjaro Christian
15 Medical University College, Moshi Tanzania

16 ⁶Kilimanjaro Christian Medical University College, Moshi Tanzania

17 ⁷National Institute for Medical Research, Headquarters, Dar es Salaam, Tanzania.

18 ⁸National Malaria Control Program (NMCP), Dodoma, Tanzania

19 ⁹CDC Foundation (CDCF), Atlanta, GA, USA

20 ¹⁰World Health Organization (WHO) Country Office, Dar es Salaam, Tanzania

21 ¹¹Faculty of Pharmaceutical Sciences, Monash University, Melbourne, Australia

22 ¹²Harvard T. C Chan School of Public Health, Boston, MA, USA

23

24 **Running Title:** Lack of *pfhrp2* and *pfhrp3* gene deletions in Tanzania

25

26 **WORD COUNT**

27 Abstract: 199

28 Main Text: 4011

29

30

31 **Footnotes**

32

33 This work was supported by The Global Fund, CDC and DELGEME Project.

34

35 The authors declare they have no competing interests. None of the material has been presented or
36 published previously.

37

38

39

40 *Corresponding author: deusishe@yahoo.com

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 **ABSTRACT**

58 **Background:** Despite recent reports of false negative results among histidine-rich protein 2 (HRP2)
59 based-malaria rapid diagnostic tests (mRDTs) caused by *pfhrp2/3* gene deletions in different
60 countries, there is paucity of data in Tanzania.

61 **Methods:** This study assessed the status of *pfhrp2/3* deletions in 7,543 blood samples using
62 laboratory multiplex antigen detection (*Plasmodium* lactate dehydrogenase - pLDH, aldolase, and
63 HRP2). Samples showing mRDT false negativity or aberrant relationship of HRP2 to pan-
64 *Plasmodium* antigens were genotyped for *pfhrp2/3* genes.

65 **Results:** Of all samples, 2,417 (32.0%) were positive for any *Plasmodium* antigens while 5,126
66 (68.0%) were negative. About 99.8% (n=2,411) of antigen positive samples had HRP2, but 6
67 (0.2%) had only pLDH and/or pAldolase. Thirteen samples had atypical relationships between pan-
68 *Plasmodium* antigens and HRP2, but were positive by PCR. An additional 16 samples with negative
69 HRP2 mRDTs but positive by microscopy were also chosen; all giving 35 samples genotyped for
70 *pfhrp2/3*. Of 35 samples, 4 (11.4%) failed to consistently amplify positive control genes (*pfmsp1*
71 and *pfmsp2*), and *pfhrp2* and *pfhrp3* genes were successfully amplified in 31 (88.6%) samples.

72 **Conclusions:** Lack of *pfhrp2* and/or *pfhrp3* genes deletions in *Plasmodium falciparum* parasites
73 supports continued use of HRP2-based mRDTs for routine malaria diagnosis in Tanzania.

74

75 **Keywords**

76 Tanzania; malaria; rapid diagnostic tests; histidine-rich protein 2/3; Lactate dehydrogenase,
77 aldolase, *Plasmodium falciparum*

78

79

80

81

82

83 INTRODUCTION

84 Upon successful establishment of blood-stage infection by the *Plasmodium* parasites, various
85 parasite proteins are produced and released into the host blood. Some of these proteins (also
86 referred to as antigens) are targets for malaria rapid diagnostic tests (mRDTs). Three antigen targets
87 currently in use include the *Plasmodium* lactate dehydrogenase (pLDH), *Plasmodium* aldolase
88 (pAldolase), and the *Plasmodium falciparum*-specific histidine rich protein 2 (HRP2)[1–3]. The use
89 of antigen-based mRDTs in many malaria endemic countries worldwide have profoundly improved
90 malaria case management and surveillance efforts and remains an essential diagnostic tool,
91 especially in Africa [4–7].

92 HRP2-based tests are species-specific since the antigen is only produced by *P. falciparum*, though
93 tests detecting pLDH and pAldolase have the potential to detect all human malarias [2,4,8]. HRP2 is
94 the most widely used antigen in mRDTs either alone or in combination with other antigens, due to
95 its abundance, specificity for *P. falciparum* infection, and high sensitivity and thermal stability [9].
96 Antibodies raised against HRP2 can cross-react with the *P. falciparum* HRP3 antigen due to
97 similarities in amino acid sequences and repeating epitopes [10–12]. The genes encoding for these
98 two antigens are located on different chromosomes of the *P. falciparum* genome, with *pfhrp2* on
99 chromosome 8 while *pfhrp3* gene is on chromosome 13 [13,14]. Large number of genetic deletions
100 of *pfhrp2* and/or *pfhrp3* genes in natural populations of *P. falciparum* were first reported in parasite
101 populations in Peru and subsequently in many countries including Africa [15–22].

102 Sensitivity of HRP2-based mRDTs can be affected by transportation and storage conditions outside
103 of manufacturer specifications, operator errors, low density infections, or a mutation or deletion of
104 the *pfhrp2* and/or *pfhrp3* genes in the infecting parasite strain [15–23]. In addition, the diversity in
105 parasite population and number of epitopes on HRP2 recognized by the diagnostic test antibodies
106 may modify the sensitivity of the test when dealing with different *P. falciparum* populations [24–
107 28].

108 In Tanzania, mRDTs were introduced between 2009 and 2012 and are now widely used in both
109 private and public health facilities throughout the country. Before the introduction of mRDTs in
110 Tanzania, a study conducted between 2005 and 2010 (the African Quinine Artesunate Malaria
111 Treatment Trial) found no evidence of *pfhrp2/3* gene deletions [29]. However, *pfhrp2* gene
112 deletions have been reported in the neighbouring East African countries, including Kenya [21] and
113 Rwanda [27]. In addition, a study conducted in Tanzania which analysed samples collected in 2010
114 showed evidence of sporadic occurrence of *pfhrp2/3* gene deletions in some areas [30]. Although
115 both the initial evidence (sample confirmed as microscopy positive for *P. falciparum* but negative
116 PfHRP2-detecting mRDTs) and confirmatory evidence (molecular approaches) [31] were used to
117 screen for *pfhrp2/3* gene deletions, the sample size and the geographic regions covered were
118 limited. In this study, field diagnostic results and a multiplex antigen detection assay was used to
119 investigate potential *pfhrp2/3* gene deletions in samples collected in 2017 from four regions of
120 Tanzania with persistently high malaria transmission after five years of introduction of mRDTs.

121

122 **MATERIALS AND METHODS**

123 **Study sites**

124 Samples and data were obtained from a cross-sectional survey conducted between July and
125 November 2017 in four regions of Tanzania (Geita, Kigoma, Mtwara and Ruvuma). These regions
126 were among those with persistently high malaria transmission as shown by the surveys conducted
127 from 2007 – 2017 [32–35]. The four Regions also had higher prevalence in the School Malaria
128 Parasitological Survey (SMPS) of 2014/2015 [36], and are among the 10 regions targeted by the
129 National Malaria Control Programme (NMCP) for reduction of malaria burden through the high
130 burden to high impact initiative (WHO and NMCP revised strategic plan). Two districts with high
131 prevalence in the SMPS of 2014/2015 were purposively selected from each region; Nyang’hwale
132 and Chato (Geita), Buhigwe and Uvinza (Kigoma), Mtwara DC and Nanyumbu (Mtwara) and
133 Nyasa and Tunduru (Ruvuma). Within each district, two villages were purposively selected for

134 sampling based on the malaria parasite positivity rates as reported from health facility reports,
135 making a total of 16 villages sampled all members of the selected households (HHs) were asked to
136 participate in the survey [37]. Blood samples were collected by finger prick, thin and thick films
137 were prepared, and all study participants were screened with malaria mRDT as per the
138 manufacturer's instructions. CareStart Malaria HRP2/pLDH (Pf/PAN) COMBO (AccessBio,NJ,
139 USA) mRDTs were used in Geita and Kigoma regions, and Lundo village of Nyasa District
140 (Ruvuma region) while CareStart Malaria HRP2 (Pf) (AccessBio,NJ, USA) were used in the rest of
141 the villages in Ruvuma and Mtwara regions. The results were interpreted within the specified
142 reading time of the manufacturer's protocol. Dried blood spots on filter papers (DBS) were
143 collected on Whatman 3MM paper (GE Healthcare, PA, USA), dried for 2-4 hours, and individually
144 packaged in sealable plastic bags with desiccant for further laboratory analysis. Participants with
145 mRDT positive results were treated according to the national guidelines [38].

146

147 The main study and the laboratory analyses reported in this manuscript obtained ethical approval
148 from the Medical Research Coordinating Committee (MRCC) of the National Institute for Medical
149 Research (NIMR), and permission to conduct the study in the selected regions was sought from the
150 President's Office, Regional Administration and Local Government Authority and Regional, District
151 and village authorities. Informed consent/assent was sought before conducting the demographic
152 survey or including the participants into the study. The laboratory activities undertaken at CDC
153 were considered non-research by the CDC Human Subjects office for the purpose of providing
154 laboratory testing of these specimens and participation of CDC scientists for this collaboration.

155

156 **Microscopy**

157 Thick and thin blood films for parasite counting and species identification were prepared from the
158 finger prick blood and stained using 2.5–3% Giemsa for 45–60 minutes. The films were examined
159 by trained microscopists to detect parasite infection status and parasite density using thick films

160 while parasite species were assessed on thin films. Parasites were counted as asexual parasites per
161 200 White Blood Cells (WBCs) for asexual parasites or 500 WBCs for sexual stages. A blood film
162 was declared negative if no *Plasmodium* parasites were detected after examining 200 high power
163 fields for the thick film. Parasite density (parasites per μL of blood) was calculated by multiplying
164 the number of asexual parasites by 40 or sexual stages by 16 assuming one microliter of blood
165 contained 8000 WBC.

166

167 **Sample processing and Laboratory Multiplex Assay**

168 DBS were shipped to the Malaria Laboratory, Centers for Disease Control and Prevention, Atlanta,
169 under ambient temperature. A 6mm punch of each sample was taken and eluted in blocking buffer
170 containing: PBS, 0.5% polyvinyl alcohol (Sigma, St. Louis, MO), 0.8% polyvinylpyrrolidone
171 (Sigma), 0.1% casein (ThermoFisher Scientific, Waltham, MA), 0.5% BSA (Sigma), 0.3% Tween-
172 20, 0.05% sodium azide, and 0.01% *E. coli* extract to prevent non-specific binding. The elution step
173 diluted the samples to a 1:20x whole blood dilution, which was the dilution used for the assay. DBS
174 samples were screened by a bead-based multiplex antigen assay for the simultaneous detection of *P.*
175 *falciparum* HRP2 (HRP2), pan-*Plasmodium* aldolase (pAldolase), and pan-*Plasmodium* lactate
176 dehydrogenase (pLDH) by previously-described protocol [39]. Antibodies used to detect epitopes
177 on HRP2 would also bind to the same epitopes on the HRP3 antigen. Protocol details are outlined in
178 the Supplemental Data.

179

180 **DNA Extraction, PET-PCR, *pfhrp2* and *pfhrp3* genotyping**

181 For samples selected for further molecular characterization, genomic DNA was extracted from DBS
182 using the QIAamp DNA Mini Kit (Hilden, Germany) using manufacturers protocol and screened
183 for parasite DNA using the multiplex photo-induced electron transfer PCR (PET-PCR) assay as
184 previously described [40–43]. PCR for *pfhrp2* and *pfhrp3* genotyping was performed as described
185 previously [44,45]. Complete details for the molecular assays are outlined in Supplemental Data:
186 (Supplemental Table1; Details of Primers and PCR reaction conditions to amplify *pfhrp2* and

187 *pfhrp3* genes and Supplemental Table 2; Details of Primers and PCR reaction conditions to amplify
188 *msh-1* and *msh-2* genes).

189

190

191 **Data analysis**

192 The database and the different data collection applications were created using the Open Data Kit
193 (ODK) software. Data cleaning, validation and quality control were undertaken as described by
194 Chiduo *et al* [37]. The data was later transferred to Microsoft Excel (Redmond, WA, USA) and
195 STATA software (Texas, USA) used for analysis which involved generating a summary of basic
196 features of the study population.

197 To determine if a sample's laboratory mean fluorescence intensity minus background signal (MFI-
198 bg) was to be denoted as positive for a specific antigen, two methods were employed. First, a panel
199 of 24 known negative blood samples which had been eluted from Whatman 903 filter paper were
200 run by the multiplex antigen assay, the lognormal mean and standard deviation was derived from
201 this sample set. The mean +3sd was calculated to provide a MFI-bg threshold signal which was
202 used as a cutoff to define antigen positive samples. Second, a two-component finite mixture model
203 was used for the log-transformed antigen MFI-bg data from the study, and the mean +3sd of the first
204 component was used to define this cutoff. In order to reduce Type I errors, the more conservative of
205 these two methods was used to determine the MFI-bg signal where any sample values above this
206 would be considered a true positive for that particular antigen [46].

207 In comparing HRP2 antigen signal to either of the pan-*Plasmodium* markers, the typical relationship
208 between these two antigens was defined as the standard correlation observed for the vast majority of
209 the observations. Visual outliers to this standard correlation were identified as outliers with
210 suspicion of aberrant HRP2 production by the *P. falciparum* parasite requiring further molecular
211 investigation.

212

213 **RESULTS**

214 A total of 2,520 households with 7,313 individuals were sampled for the cross-sectional survey,
215 which was conducted in 16 villages (in 8 districts) from four regions of Tanzania (Geita, Kigoma,
216 Mtwara and Ruvuma) between July and November 2017 (Table 1). Apart from the 7,313 individuals
217 enrolled, an additional of 230 samples were taken from individuals who came to seek health
218 services, but were not among the 120 sampled households. Therefore, 7,543 blood samples were
219 available for this study, and 3.0% (230/7,543) of these were from individuals with incomplete data.
220 The remainder (97.0%, 7,313/7,543) had complete data with parasitological, clinical and
221 demographic information. The mean age in years was 22.3 (SD=21.0), and 43.4% of participants
222 were male (Table 1).

223

224 For all persons enrolled in all study sites, 38.4% (2897/7543) were positive for any one of the three
225 parasite detection assays: microscopy, mRDT, or bead-based multiplex assay. The results showed
226 15.8% (1,158/7,313) of the persons were positive for *P. falciparum* infection by microscopy, 33.3%
227 (2,437/7,313) were positive by HRP2 mRDT, and 32.0% (2,417/7,543) were positive for any one of
228 the *Plasmodium* antigens tested by the bead-based multiplex assay. Concordance among these three
229 malaria tests is shown in Supplemental Figure 1. For those positive by microscopy, the geometric
230 mean parasite density was 575 asexual parasites/ μ L of blood.

231

232 A flow diagram for sample selection for further molecular testing to detect the presence (and
233 potential prevalence) of *pfhrp2* and *pfhrp3* deletions in this study population is shown in Figure 2.
234 In selecting specimens warranting molecular assays for *pfhrp2* and *pfhrp3* genotyping, two types of
235 information were considered: discordance between field microscopy and mRDT results for an
236 individual, and relationship between the pan-*Plasmodium* antigens and the HRP2 antigen for an
237 individual's blood sample. From the field tests (microscopy and mRDT), 95 persons were found to
238 be microscopy positive but mRDT negative (1.3% of the 7313 persons who had data for both tests).
239 Of these 95 persons, 94 had a DBS available for multiplex antigen detection, and 54.3% (51/94) of

240 these were found to be HRP2 antigen positive by the laboratory test with a typical relationship to
241 the other pan-*Plasmodium* antigens (as illustrated in Figure 3). Additionally, 28.7% (27/94) of these
242 samples were negative for *P. falciparum* DNA and could not undergo genotyping. The remaining 16
243 samples (17.0% of the 94 selected by microscopy/mRDT discordance) were all *P. falciparum* DNA
244 positive, but had no antigens detected (n=7) or an atypical relationship between the pan-
245 *Plasmodium* markers and HRP2 (n=9). Based on these test results, these 16 were selected as
246 warranting *pfhrp2* and *pfhrp3* genotyping.

247

248 Since all DBS were screened by the multiplex antigen assay, in addition to samples selected for
249 genotyping by the field diagnostic tests, samples could be selected for *pfhrp2* and *pfhrp3*
250 genotyping based solely on laboratory results. Of all 7,543 DBS screened by the multiplex antigen
251 assay, malaria antigen could not be detected in 5,126 (68.0%) samples. Of the 2,417 DBS positive
252 for any antigens, 2,398 (99.2%) of these were found to have a typical relationship of the pan-
253 *Plasmodium* markers with HRP2 (Figure 3). Of the remaining 19 DBS which were all positive for
254 the pan-*Plasmodium* antigens; 6 had a complete absence of HRP2 antigen, and 13 had an atypical
255 relationship between the assay signal for the pan marker and HRP2. All of these 19 were positive
256 for *P. falciparum* DNA and could thus be utilized for genotyping PCRs. Together with the 16
257 samples chosen initially based on field test results, these 35 samples (16 + 19) were gathered as the
258 final set with suspicion of aberrant HRP2 and/or HRP3 antigen production and warranted
259 genotyping for the *pfhrp2* and *pfhrp3* genes.

260

261 Table 2 outlines the *pfhrp2* and *pfhrp3* genotyping results for these 35 samples, as well as other
262 information regarding characteristics of the individuals, field test results, and other factors. Most of
263 the samples (31/35, 88.6%) were found to successfully amplify the *pfhrp2* and *pfhrp3* genes for the
264 two exons of each gene. However, one or more of the *pfhrp2* and *pfhrp3* exon targets could not be
265 amplified for 4 (11.4%) DNA samples. To correctly report the presence of a deletion (i.e. lack of

266 PCR amplification), we chose to include amplification targets for two other single-copy genes
267 (*pfmsp1* and *pfmsp2*) to verify true non-amplification event [31]. For these 4 DNA samples, all were
268 unable to consistently amplify both *pfmsp1* and *pfmsp2* single-copy genes and were excluded in the
269 analysis. For this reason, non-amplification of *pfhrp2* and *pfhrp3* targets due to true deletion events
270 could not be verified, and thus, no deletions in these genes could be confirmed in the remaining 31
271 samples.

272

273 **DISCUSSION**

274 The samples used in this study were collected during a community-based survey which was
275 conducted in four regions with persistently high malaria burden over the past 10yrs and used to
276 assess the presence and prevalence of *pfhrp2* and *pfhrp3* gene deletions in Tanzania. The findings
277 from field mRDT and microscopy tests as well as the laboratory multiplex antigen test indicate that
278 the vast majority of *P. falciparum* infections in Tanzania produced high levels of HRP2 (and HRP3)
279 antigens which would be recognized by HRP2-based mRDTs. Although mRDTs did not detect some
280 infections from persons confirmed to be *P. falciparum* positive by PCR, the evidence presented here
281 suggests that these false negative mRDT results were not due to *pfhrp2* and *pfhrp3* gene deletion,
282 and more a factor of low parasite density infections.

283

284 During the survey, extensive efforts were taken to protect the quality of the mRDTs. The
285 experienced study team ensured that mRDTs were stored in appropriate conditions as per the
286 manufacturers' instructions; transported in good conditions (ambient temperature with minimal
287 humidity) and the tests were also performed by experienced technician. To minimize operator
288 errors, the testing process and reading of mRDT results were done in the presence of other members
289 of the team who ensured that any doubtful mRDTs results were correctly read and interpreted.
290 Studies conducted elsewhere reported that the performance of HRP2-based mRDTs depends on the
291 level of parasitaemia [1,8,47], with the lower limit of detection generally around 200 parasites/ μ L

292 [1]. This community survey included mainly asymptomatic persons, and some had low-level (sub-
293 detectable by mRDT) parasitaemia; this could possibly explain some of the discordance between
294 the field mRDT results and the laboratory antigen test. In total 1,998 (27.3% of all) persons were
295 concordant between those two tests, whereas 372 (6.0%) individuals were positive for the mRDT
296 alone and 325 (4.4%) were positive only by the laboratory antigen test. As mRDTs are designed for
297 reliable detection of parasite densities more typical of clinical relevance (200p/uL or greater), their
298 use in the asymptomatic population may miss low-density infections and HRP2 levels [46]. Even in
299 this community setting, it was encouraging to see that mRDTs were able to detect the majority of
300 persons with malaria antigenemia as determined by the laboratory antigen test. Of 2,323 total
301 samples found to be antigen positive, 1,998 (86.0%) came from persons who were mRDT positive.
302 Considering the generally low parasite densities for any *P. falciparum*-infected persons in this
303 survey, concordance was also good for all three tests; microscopy, RDTs, and the laboratory antigen
304 test. Of 1,158 total microscopy positives, 1,063 (91.8%) were also mRDT positive, and 1,050
305 (90.7%) were also positive by the laboratory antigen test. Concordance among multiple malaria
306 indicators provides greater confidence for the true levels of malaria in a populace.

307

308 Of the 35 samples selected for further molecular investigation, which were positive for *P.*
309 *falciparum* by PCR, the majority (27/35) had relatively low parasite densities ranging from 0 to
310 1,000 parasite/ μ l. However, eight samples were from persons with higher parasite densities (>1,000
311 asexual parasites/ μ l), and two of these samples had very high parasite density (88,600 and 104,000
312 parasite/ μ l). Two of these eight persons gave negative mRDT results which could potentially be
313 explained by the prozone effect where excess of antigen leads to false-negative results [48]. All
314 eight of these higher density infections were found to have detectable HRP2 antigen, though at
315 much lower blood concentrations than typical given those levels of *P. falciparum* parasite densities.

316

317 The multiplex antigen screening allowed for reconfirmation of HRP2 (and possibly HRP3) antigen
318 profiles for DBS samples. Of all 7,543 samples screened by the multiplex antigen test, few (28,
319 0.4%) samples had a complete absence of HRP2 or an aberrant relationship between the assay
320 signal for the pan marker and HRP2. This could be due to very low parasite densities or infection
321 with a non-*P. falciparum* infection, but this observation could not be explained by deletions of the
322 *pfhrp2* and *pfhrp3* genes.

323

324 Our report adds to the literature in the same way as studies in Honduras [45] and French Guiana
325 [49] where no deletion of *pfhrp2* gene were reported. However, these findings are in contrast with
326 the results from a recent study which was conducted in Mbeya, Mtwara, and Mwanza regions in
327 Tanzania using samples collected in 2010, one year following the introduction of mRDTs. That
328 study found evidence of sporadic occurrence of *pfhrp2* and *pfhrp3* gene deletion in some areas, with
329 1.7% of isolates tested reported to have a deletion of either of the genes [30]. Though recommended
330 molecular tests [31] were used in this study, the overall study was very small with only 176
331 Tanzanian samples tested. Malaria endemicity and year of sampling could potentially explain the
332 different results between the present and the previous surveys, but with the very low estimates for
333 prevalence from the 2010 study, there is a potential that those parasite strains are still present at very
334 low- levels in these regions.

335

336 A limitation of the current study is that single gene deletions of *pfhrp2* or *pfhrp3* alone could be
337 masked by a parasite producing at least one of these antigens. Deletions (or loss-of-function
338 mutations) in both genes would lead to a complete absence of HRP2/HRP3 antigens in a *P.*
339 *falciparum* infection. However, if one of these antigens was being produced by the parasite, the
340 algorithm defined here may not identify the blood sample as suspicious if the assay signal for HRP2
341 remains high. Additionally, the molecular tests performed here were only for complete gene
342 deletions, and any loss-of-function point mutations leading to antigen non-expression would not be

343 captured since the *pfhrp2* or *pfhrp3* specific DNA amplification would still occur using the current
344 protocol. Another limitation from the study is that it does not provide estimates for entire country,
345 since only 4 out of the 26 regions of mainland Tanzania were included in this study. Further studies
346 would need to be conducted on *P. falciparum* isolates collected from other geographical regions of
347 Tanzania (especially in low transmission areas) in order to increase the chances of detecting *pfhrp2*
348 and *pfhrp3* gene deletion in different parts of the country.

349

350 **CONCLUSIONS**

351 Though a low number of false negative mRDT results were found in Tanzania, these could not be
352 explained by *pfhrp2* or *pfhrp3* gene deletions. Overall the study results suggest that HRP2-based
353 mRDTs for detection of *P. falciparum* infection and confirmatory diagnosis of malaria in the
354 surveyed area in Tanzania can be used as a reliable tool for malaria case management.

355

356 **Funding**

357 The field component of this study was supported by The Global Fund through National Malaria
358 Control Programme of the Tanzanian Ministry of Health. The CDC laboratory work was supported
359 by Malaria Branch and Catherine Bakari's MSc studies was funded by the Developing Excellence
360 in Leadership and Genomics for Malaria Elimination (DELGEME) project with funding from the
361 Developing Excellence in Leadership and Training (DELTA) Africa Initiative, of the African
362 Academy of Sciences (AAS).

363

364 **Acknowledgments**

365 The authors would like to thank the survey teams and study participants for their involvement in the
366 survey in which the tested samples were collected. CB and DSI are supported by DELGEME
367 through the DELTA Africa Initiative (DELGEME grant 107740/Z/15/Z). The DELTA Africa
368 Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance

369 for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for
370 Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the
371 Wellcome Trust (DELGEME grant 107740/Z/15/Z) and the UK government. The views expressed
372 in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency,
373 Wellcome Trust, or the UK government.

374

375

376 **Conflict of Interests**

377 The authors declare no competing financial interests.

378

379 **Author Contributions**

380 Coordination of field surveys: C.I.M., M.G.C., S.R., F.C., F.M., R.M., S.M., A.M., C.K.K., S.G.N.,
381 D.S.I. Conceived and designed experiments: V.U., E.R., D.S.I. Performed the experiments: C.B.,
382 S.J., G.S., C.H., D.P.N., E.R. Analyzed the data: C.B., E.R., D.S.I. Contributed reagents, materials,
383 and analysis tools: V.U., E.R. Manuscript preparation: C.B., V.U., E.R., D.S.I. All authors reviewed
384 and approved the final manuscript.

385

386 **Disclaimer**

387 The findings and conclusions presented in this report are those of the authors and do not necessarily
388 reflect the official position of the Centers for Disease Control and Prevention. Ritha Njau is a staff
389 member of the World Health Organization. She alone is responsible for the views expressed in this
390 publication, which do not necessarily represent the decisions, policy or views of the World Health
391 Organization.

392

393 **REFERENCES**

394 1. Moody A. Rapid Diagnostic Tests for Malaria Parasites. **2002**; 15(1):66–78.

- 395 2. WHO. New Perspectives: Malaria Diagnosis: Report of a Joint WHO/USAID Informal
396 Consultation. Who [Internet]. **2000**; (October 1999):1–29. Available from:
397 http://www.who.int/malaria/publications/atoz/who_cds_rbm_2000_14/en/%0Ahttp://www.who.int/tdr/publications/documents/malaria-diagnosis.pdf
- 399 3. Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in endemic settings. *Clin*
400 *Microbiol Infect* [Internet]. European Society of Clinical Infectious Diseases; **2013**;
401 19(5):399–407. Available from: <http://dx.doi.org/10.1111/1469-0691.12151>
- 402 4. Bell D, Wongsrichanalai C, Barnwell JW et al. Ensuring quality and access for malaria
403 diagnosis: How can it be achieved? *Nat Rev Microbiol*. **2006**; 4(9):682–695.
- 404 5. Masanja MI, McMorro M, Kahigwa E, Kachur SP, McElroy PD. Health workers’ use of
405 malaria rapid diagnostic tests (RDTS) to guide clinical decision making in rural dispensaries,
406 Tanzania. *Am J Trop Med Hyg*. **2010**; 83(6):1238–1241.
- 407 6. Rutta ASM, Francis F, Mmbando BP, et al. Using community-owned resource persons to
408 provide early diagnosis and treatment and estimate malaria burden at community level in
409 north-eastern Tanzania. *Malar J*. **2012**; 11:1–8.
- 410 7. Thiam S, Thior M, Faye B, et al. Major Reduction in Anti-Malarial Drug Consumption in
411 Senegal after Nation-Wide Introduction of Malaria Rapid Diagnostic Tests. *PLoS One*. **2011**;
412 6(4).
- 413 8. Murray CK, Gasser RA, Magill AJ, Miller RS. Update on rapid diagnostic testing for
414 malaria. *Clin Microbiol Rev*. **2008**; 21(1):97–110.
- 415 9. WHO. Global Malaria Programme WHO: World Malaria Report 2012. **2012**; :V–195.
- 416 10. Rock EP, Marsh K, Taylor DW, et al. Comparative analysis of the *Plasmodium falciparum*
417 histidine-rich proteins HRP-I, HRP-II and HRP-III in malaria parasites of diverse origin.
418 *Parasitology*. **1987**; 95(2):209–227.
- 419 11. Lee N, Baker J, Andrews KT, et al. Effect of sequence variation in *Plasmodium falciparum*
420 histidine-rich protein 2 on binding of specific monoclonal antibodies: Implications for rapid

- 421 diagnostic tests for malaria. *J Clin Microbiol.* **2006**; 44(8):2773–2778.
- 422 12. Lee N, Gatton ML, Pelecanos A, et al. Identification of optimal epitopes for *Plasmodium*
423 *falciparum* rapid diagnostic tests that target histidine-rich proteins 2 and 3. *J Clin Microbiol.*
424 **2012**; 50(4):1397–1405.
- 425 13. Wellems TE, Howard RJ. Homologous genes encode two distinct histidine-rich proteins in a
426 cloned isolate of *Plasmodium falciparum*. *Proc Natl Acad Sci U S A* [Internet]. **1986**;
427 83(16):6065–9. Available from:
428 <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=386439&tool=pmcentrez&render>
429 [type=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=386439&tool=pmcentrez&render)
- 430 14. Kemp DJ, Thompson JK, Walliker D, Corcoran LM. Molecular karyotype of *Plasmodium*
431 *falciparum*: conserved linkage groups and expendable histidine-rich protein genes. *Proc Natl*
432 *Acad Sci.* **2006**; 84(21):7672–7676.
- 433 15. Gamboa D, Ho MF, Bendezu J, et al. A large proportion of *P. falciparum* isolates in the
434 Amazon region of Peru lack *pfhrp2* and *pfhrp3*: Implications for malaria rapid diagnostic
435 tests. Bjorkman A, editor. *PLoS One* [Internet]. Public Library of Science; **2010** [cited 2018
436 Apr 6]; 5(1):e8091. Available from: <http://dx.plos.org/10.1371/journal.pone.0008091>
- 437 16. Maltha J, Gamboa D, Bendezu J, et al. Rapid Diagnostic Tests for Malaria Diagnosis in the
438 Peruvian Amazon: Impact of *pfhrp2* Gene Deletions and Cross-Reactions. *PLoS One.* **2012**;
439 7(8):1–7.
- 440 17. Koita OA, Doumbo OK, Ouattara A, et al. False-negative rapid diagnostic tests for malaria
441 and deletion of the histidine-rich repeat region of the *hrp2* gene. *Am J Trop Med Hyg.* **2012**;
442 86(2):194–198.
- 443 18. Berhane A, Russom M, Bahta I, Hagos F, Ghirmai M, Uqubay S. Rapid diagnostic tests
444 failing to detect *Plasmodium falciparum* infections in Eritrea: An investigation of reported
445 false negative RDT results. *Malar J. BioMed Central*; **2017**; 16(1):1–6.
- 446 19. Parr JB, Verity R, Doctor SM, et al. *Pfhrp2* -Deleted *Plasmodium falciparum* Parasites in the

- 447 Democratic Republic of the Congo: A National Cross-sectional Survey. *J Infect Dis.* **2017**;
448 216(1):36–44.
- 449 20. Viana GMR, Okoth SA, Silva-Flannery L, et al. Histidine-rich protein 2 (pfhrp2) and pfhrp3
450 gene deletions in *Plasmodium falciparum* isolates from select sites in Brazil and Bolivia.
451 *PLoS One.* **2017**; 12(3):1–13.
- 452 21. Beshir KB, Sepúlveda N, Bharmal J, et al. *Plasmodium falciparum* parasites with histidine-
453 rich protein 2 (pfhrp2) and pfhrp3 gene deletions in two endemic regions of Kenya. *Sci Rep.*
454 **2017**; 7(1):1–10.
- 455 22. Bharti PK, Chandel HS, Ahmad A, Krishna S, Udhayakumar V, Singh N. Prevalence of
456 pfhrp2 and/or pfhrp3 gene deletion in *plasmodium falciparum* population in eight highly
457 endemic states in India. *PLoS One.* **2016**; 11(8):1–16.
- 458 23. Baker J, McCarthy J, Gatton M, et al. Genetic Diversity of *Plasmodium falciparum*
459 Histidine-Rich Protein 2 (PfHRP2) and Its Effect on the Performance of PfHRP2-Based
460 Rapid Diagnostic Tests. *J Infect Dis* [Internet]. **2005**; 192(5):870–877. Available from:
461 <https://academic.oup.com/jid/article-lookup/doi/10.1086/432010>
- 462 24. Wurtz N, Fall B, Bui K, et al. Pfhrp2 and pfhrp3 polymorphisms in *Plasmodium falciparum*
463 isolates from Dakar, Senegal: Impact on rapid malaria diagnostic tests. *Malar J.* **2013**;
464 12(1):1–8.
- 465 25. Atroosh WM, Al-Mekhlafi HM, Al-Jasari A, et al. Genetic variation of pfhrp2 in *Plasmodium*
466 *falciparum* isolates from Yemen and the performance of HRP2-based malaria rapid
467 diagnostic test. *Parasites and Vectors* [Internet]. *Parasites & Vectors*; **2015**; 8(1):1–8.
468 Available from: <http://dx.doi.org/10.1186/s13071-015-1008-x>
- 469 26. Li P, Xing H, Zhao Z, et al. Genetic diversity of *Plasmodium falciparum* histidine-rich
470 protein 2 in the China-Myanmar border area. *Acta Trop.* **2015**; 152:26–31.
- 471 27. Kozycki CT, Umulisa N, Rulisa S, et al. False-negative malaria rapid diagnostic tests in
472 Rwanda: impact of *Plasmodium falciparum* isolates lacking hrp2 and declining malaria

- 473 transmission. *Malar J.* **2017**; 16(1):1–11.
- 474 28. Gendrot M, Fawaz R, Dormoi J, Madamet M, Pradines B. Genetic diversity and deletion of
475 *Plasmodium falciparum* histidine-rich protein 2 and 3: a threat to diagnosis of *P. falciparum*
476 malaria. *Clin Microbiol Infect* [Internet]. Elsevier Ltd; **2018**; :2–7. Available from:
477 <https://doi.org/10.1016/j.cmi.2018.09.009>
- 478 29. Ramutton. T, Hendriksen. IC, Mwanga-Amumpaire. J, et al. Sequence variation does not
479 confound the measurement of plasma PfHRP2 concentration in African children presenting
480 with severe malaria. *Malar J* [Internet]. **2012**; 11:276. Available from:
481 <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L52169263>
482 [%0Ahttp://dx.doi.org/10.1186/1475-2875-11-](http://dx.doi.org/10.1186/1475-2875-11-276)
483 [276%0Ahttp://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=14752875&id=doi:10.1186%2F](http://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=14752875&id=doi:10.1186%2F1475-2875-11-276&atitle=Sequence+variation+does+no)
484 [1475-2875-11-276&atitle=Sequence+variation+does+no](http://sfx.library.uu.nl/utrecht?sid=EMBASE&issn=14752875&id=doi:10.1186%2F1475-2875-11-276&atitle=Sequence+variation+does+no)
- 485 30. Thomson R, Beshir KB, Cunningham J, et al. Title:pfhrp2 and pfhrp3 gene deletions that
486 affect malaria rapid diagnostic tests for for *Plasmodium falciparum*: analysis of archived
487 blood samples from three African countries. **2019**; .
- 488 31. Cheng Q, Gatton ML, Barnwell J, et al. *Plasmodium falciparum* parasites lacking histidine-
489 rich protein 2 and 3: a review and recommendations for accurate reporting. *Malar J*
490 [Internet]. **2014**; 13(1):283. Available from:
491 [http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4115471&tool=pmcentrez&rende](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4115471&tool=pmcentrez&rendertype=abstract)
492 [rtype=abstract](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4115471&tool=pmcentrez&rendertype=abstract)
- 493 32. TACAIDS. Tanzania 2007-08 HIV/AIDS and Malaria Indicator Survey Key Findings.
494 Tanzania 2007-08 HIV/AIDS Malar Indic Surv Key Find. **2008**; (HIV Prevalence):16.
- 495 33. TACAIDS. Tanzania- 2011-12 HIV/AIDS and Malaria Indicator Survey 2011-12: Key
496 Findings. Tanzania Comm AIDS (ZAC), Zanzibar AIDS Comm (NBS), Natl Bur Stat
497 (OCGS), Off Chief Gov Stat ICF Int. **2013**; :16.
- 498 34. TDHS-MIS. Tanzania Demographic and Health Survey and Malaria Indicator Survey

- 499 (TDHS-MIS) 2015-16. Dar es Salaam, Tanzania, Rockville, Maryl USA [Internet]. **2016**;
500 :172–173. Available from: <https://www.dhsprogram.com/pubs/pdf/FR321/FR321.pdf>
- 501 35. THIS. Summary Sheet: Preliminary Findings 2016-2017. **2017**; (December 2017):2016–
502 2017. Available from: [http://www.nbs.go.tz/nbs/takwimu/this2016-](http://www.nbs.go.tz/nbs/takwimu/this2016-17/Tanzania_SummarySheet_English.pdf)
503 [17/Tanzania_SummarySheet_English.pdf](http://www.nbs.go.tz/nbs/takwimu/this2016-17/Tanzania_SummarySheet_English.pdf)
- 504 36. Chacky F, Runge M, Rumisha SF, et al. Nationwide school malaria parasitaemia survey in
505 public primary schools, the United Republic of Tanzania. *Malar J* [Internet]. BioMed Central;
506 **2018**; 17(1):1–16. Available from: <https://doi.org/10.1186/s12936-018-2601-1>
- 507 37. Chiduo MG, Mandara CI, Rumisha SF, et al. Assessing the intrinsic and extrinsic drivers and
508 targeting the observed resilience of malaria in northwestern and southern Tanzania: A
509 protocol for a cross-sectional exploratory study. **2020**; :1–46.
- 510 38. MoH. National Guidelines for Diagnosis and Treatment of Malaria. Dar es Salam, Tanzania:
511 Ministry of Health and Social Welfare, United Republic of Tanzania; **2006**; (January).
- 512 39. Plucinski MM, Cruz KR, Ljolje D, et al. Screening for Pfhrrp2/3 -Deleted Plasmodium
513 falciparum , Non- falciparum , and Low-Density Malaria Infections by a Multiplex Antigen
514 Assay. *J Infect Dis*. **2018**; 219(3):437–447.
- 515 40. Lucchi NW, Karell MA, Journel I, et al. PET-PCR method for the molecular detection of
516 malaria parasites in a national malaria surveillance study in Haiti, 2011. *Malar J*. **2014**;
517 13:462.
- 518 41. Akerele D, Ljolje D, Talundzic E, Venkatachalam, Udhayakumar Lucchi WN. Molecular
519 diagnosis of malaria by photo-induced electron transfer fluorogenic primers (PET-PCR). *Am*
520 *J Trop Med Hyg* [Internet]. **2017**; Conference:258. Available from:
521 [http://www.ajtmh.org/content/87/5_Suppl_1/226.full.pdf+html%5Cnhttp://ovidsp.ovid.com/o](http://www.ajtmh.org/content/87/5_Suppl_1/226.full.pdf+html%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=71041482%5Cnhttp://eleanor.lib.gla.ac.uk:4550/resserv?sid=OVID:embase&id=pmid:&id=doi:&issn=0002-9637&isbn=&volum)
522 [vidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=71041482%5Cn](http://www.ajtmh.org/content/87/5_Suppl_1/226.full.pdf+html%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=71041482%5Cnhttp://eleanor.lib.gla.ac.uk:4550/resserv?sid=OVID:embase&id=pmid:&id=doi:&issn=0002-9637&isbn=&volum)
523 [http://eleanor.lib.gla.ac.uk:4550/resserv?sid=OVID:embase&id=pmid:&id=doi:&issn=0002-](http://eleanor.lib.gla.ac.uk:4550/resserv?sid=OVID:embase&id=pmid:&id=doi:&issn=0002-9637&isbn=&volum)
524 [9637&isbn=&volum](http://eleanor.lib.gla.ac.uk:4550/resserv?sid=OVID:embase&id=pmid:&id=doi:&issn=0002-9637&isbn=&volum)

- 525 42. Kudyba HM, Louzada J, Ljolje D, et al. Field evaluation of malaria malachite green loop-
526 mediated isothermal amplification in health posts in Roraima state, Brazil. *Malar J* [Internet].
527 BioMed Central; **2019**; 18(1):1–7. Available from: [https://doi.org/10.1186/s12936-019-2722-](https://doi.org/10.1186/s12936-019-2722-1)
528 1
- 529 43. Sitali L, Miller JM, Mwenda MC, et al. Distribution of Plasmodium species and assessment
530 of performance of diagnostic tools used during a malaria survey in Southern and Western
531 Provinces of Zambia. *Malar J* [Internet]. BioMed Central; **2019**; 18(1):1–9. Available from:
532 <https://doi.org/10.1186/s12936-019-2766-2>
- 533 44. Akinyi S, Magill AJ, Torres K, et al. Multiple genetic origins of histidine-rich protein 2 gene
534 deletion in Plasmodium falciparum parasites from Peru. *Sci Rep*. **2013**; 3(1):1–8.
- 535 45. Abdallah JF, Okoth SA, Fontecha GA, et al. Prevalence of pfhrp2 and pfhrp3 gene deletions
536 in Puerto Lempira, Honduras. *Malar J*. **2015**; 14(1):1–9.
- 537 46. Plucinski M, Dimbu R, Candrinho B, et al. Malaria surveys using rapid diagnostic tests and
538 validation of results using post hoc quantification of Plasmodium falciparum histidine-rich
539 protein 2. *Malar J*. BioMed Central; **2017**; 16(1):1–7.
- 540 47. Benton CB, Nazha A, Pemmaraju N, et al. *HHS Public Access*. **2016**; 95(2):222–242.
- 541 48. Luchivez J, Baker J, Alcantara S, et al. Laboratory demonstration of a prozone effect HRP2
542 detecting malaria diagnostic tests: implications for clinical management. *Malar J* [Internet].
543 **2011**; 10:1–7. Available from: <http://dx.doi.org/10.1186/1475-2875-10-286>
- 544 49. Trouvay M, Palazon G, Berger F, et al. High Performance of Histidine-Rich Protein 2 Based
545 Rapid Diagnostic Tests in French Guiana are Explained by the Absence of pfhrp2 Gene
546 Deletion in *P. falciparum*. *PLoS One*. **2013**; 8(9):1–7.
- 547
- 548
- 549

550 **Tables**

551 **Table 1: Baseline characteristics of individuals sampled in each of the four regions**

	Mtwara	Geita	Kigoma	Ruvuma	Total
Number of HHs registered	1,306	1,209	1,490	2,202	6,207
Number of HHs sampled n (%)	684 (27.1)	533 (21.2)	587 (23.3)	716 (28.4)	2,520 (40.5)
Number of individuals in HHs	4,723	6,994	7,945	8,699	28,361
Number of individual sampled; n (%)	1,548 (21.2)	2,053 (28.1)	1,979 (27.1)	1,733 (23.7)	7,313 (25.8)
Age in years; mean (SD)	25.3 (22.1)	18.2 (18.2)	22.4 (22.1)	24.3 (21.3)	22.3 (21.0)
Sex = Male; n (%)	702 (22.1)	878 (27.7)	850 (26.8)	742 (23.4)	3,172 (43.4)
Microscopy positive; n (%)*	209 (13.9)	361 (24.0)	558 (37.1)	378 (25.1)	1,506 (20.6)
mRDTs positive n(%)*	553 (22.7)	556 (22.8)	737 (30.2)	591 (24.3)	2,437 (33.3)
Fever [†] - Yes; n (%)*	245 (16.2)	261 (17.2)	736 (48.5)	275 (18.1)	1,517 (20.5)
GMPD of positives; p/ul, (95% CI)	385 (299-495)	774 (643-931)	583 (482-706)	527 (435-638)	575 (516-637)

HH: Household

SD: standard deviation

N: number of individuals

GMPD: geometric mean parasite density

CI: Confidence interval

*N=7,313

[†]Fever within the past two weeks

552

553

554

555

556

557

558

559 **Table 2. Summary of *pfhrp2* and *pfhrp3* genotyping results for the samples selected based on**
 560 **field mRDT and microscopy results, laboratory antigen assay, or both.**

561


Sample #	Selected on:	District	Age	RDT Result	Microscopy Parasite Density (p/uL)	PET Pf Ct	pAldo (ng/mL)	pLDH (ng/mL)	HRP2 (ng/mL)	<i>pfhrp2</i> exons 1/2	<i>pfhrp3</i> exons 1/2	<i>pfmsp1</i> *	<i>pfmsp2</i> *
1	aldo	Chiulu	6	+	256	35.1	43.9	3.7	1.0	+/+	+/+		
2	aldo	Chiulu	6	-	0	35.6	40.6	2.7	0.0	+/+	+/+		
3	rdt	Chiulu	33	-	80	38.3	0.0	0.0	0.0	+/+	+/+		
4	rdt	Herembe	3	-	520	31.8	28.4	2.8	1.0	+/+	+/+		
5	ldh	Kasenga	54	+	1717	33.8	26.0	6.0	1.0	+/+	+/+		
6	ldh	Kasenga	10	+	1840	33.5	30.6	10.6	1.9	+/+	+/+		
7	aldo	Kasenga	6	+	591	35	62.3	6.0	1.7	+/+	+/+		
8	aldo	Kasenga	4	+	440	33.9	46.5	4.1	1.4	+/+	+/+		
9	rdt	Kasenga	4	-	32	35	0.0	0.0	0.0	+/+	+/+		
10	rdt	Kasenga	13	-	96	33.3	0.0	0.0	0.8	+/+	+/+		
11	rdt	Kasenga	0	-	221	33.7	0.0	0.0	0.0	+/+	+/+		
12	ldh aldo	Katale	2	+	480	31.8	360.9	114.6	21.2	+/+	+/+		
13	ldh aldo	Katale	4	+	2628	28.7	797.1	214.5	42.4	+/+	+/+		
14	ldh aldo	Katale	10	-	0	35.3	76.4	8.9	0.2	+/+	+/+		
15	ldh aldo rdt	Katale	9	-	2000	28.2	210.8	62.4	5.0	+/+	+/+		
16	aldo rdt	Katale	4	-	280	31	44.1	0.0	0.0	+/+	-/-	-/-	+/-
17	ldh aldo	Kigege	2	+	48	32.4	190.5	80.3	12.4	+/+	+/+		
18	rdt	Kigege	38	-	16	38.9	0.0	0.0	0.0	+/+	-/+	-/+	-/-
19	rdt	Kigege	8	-	520	34.8	0.0	0.0	0.0	+/+	+/+		
20	ldh	Kitunguli	6	+	0	31.5	42.9	39.2	1.5	+/+	+/+		
21	rdt	Mkwela	43	-	440	37.3	0.0	0.0	0.0	+/+	+/-	+/-	-/+
22	aldo	Mkwela	2	+	0	35.3	51.0	5.4	1.3	+/+	+/+		
23	ldh aldo	Mkwela	11	-	0	35.8	46.3	5.6	0.0	+/+	+/+		
24	aldo	Mkunwa	3	+	48	36	33.0	5.9	0.1	+/+	+/+		
25	rdt	Mtawarawa	14	-	176	33.2	0.0	0.0	0.0	+/+	+/+		
26	rdt	Mtawarawa	22	-	96	34.9	0.0	0.0	0.1	+/+	+/+		
27	ldh	Mwamila	2	+	11480	27.6	338.3	159.4	35.5	+/+	+/+		
28	ldh aldo rdt	Nyangalamila	8	-	288	34	54.7	11.0	0.0	+/+	+/+		
29	ldh aldo	Nyankoronko	7	+	104000	25.7	760.1	242.9	37.5	+/+	+/+		
30	ldh aldo	Nyankoronko	2	+	160	33.8	98.8	18.3	2.1	+/+	+/+		
31	ldh aldo	Nyankoronko	4	+	28800	29.8	76.2	19.1	0.9	+/+	+/+		
32	ldh	Nyankoronko	6	+	440	36.5	24.2	7.9	1.4	+/-	+/+	+/-	+/-
33	aldo rdt	Nyankoronko	43	-	48	37	31.3	0.0	0.0	+/+	+/+		
34	rdt	Nyankoronko	10	-	760	31.3	0.0	0.0	0.8	+/+	+/+		
35	ldh rdt	Nyankoronko	9	-	88600	25.5	187.5	85.1	16.6	+/+	+/+		

*, Antigen listed indicates aberrant relationship between HRP2 and that antigen's assay signal; mRDT indicates microscopy/mRDT discordance

†, Genotyping for *pfmsp1* and *pfmsp2* not performed if sample showed amplification for all *pfhrp2* and *pfhrp3* targets

562

563



572

573

574 **Figure 2. Flowchart for selection of samples requiring genotyping for *pfhrp2* and *pfhrp3*.**

575 Samples were selected based on initial field microscopy and mRDT results (shown on left), or

576 multiplex laboratory antigen detection (shown on right), for final determination of samples

577 requiring genotyping to detect potential deletion of *pfhrp2/3* genes.

578

579

580

581


582

583

584

585

586



587

588 **Figure 3. Scatterplots of pan-*Plasmodium* LDH or aldolase assay signal in comparison with**
589 **HRP2 assay signal.** Plots designate samples that were selected for further genotyping investigation
590 as based on an atypical relationship to the pan-*Plasmodium* LDH (A) or aldolase (B) antigens.
591 Hashed lines in each plot show MFI-bg assay signal threshold which would indicate a positive
592 assay signal for each antigen. Black circles indicate samples selected based on field RDT result as
593 well as laboratory antigen assay that were *P. falciparum* DNA positive. Red circles indicate samples
594 selected solely based on laboratory antigen assay that were *P. falciparum* DNA positive. Squares
595 indicate samples selected solely based on laboratory antigen assay that were *P. falciparum* DNA
596 negative.